Intranasal Insulin for Posttraumatic Stress Disorder

Part of paid clinical trials in West Haven, Connecticut.

Sponsor
VA Connecticut Healthcare System
Study ID
NCT04044534
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Intranasal insulin — DRUG
    Subjects in this arm will receive intranasal insulin (80 IU per day).
  • Placebo — DRUG
    Subjects in this arm will receive placebo.

Study Details

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Key Dates

Start date
Oct 31, 2024
Status verified
Sep 2025
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Intranasal insulin
    Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).
  • Experimental: Placebo
    Subjects in this arm will receive placebo.

Primary Outcome Measure

Post-traumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) [ Time Frame: 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
VA Connecticut Healthcare SystemWest HavenConnecticut06516
Gihyun Yoon, MD
[email protected]
203-932-5711

Find similar trials in West Haven, CT

By condition
PTSD (post-traumatic stress disorder)
By specialty
PsychiatryMental healthBehavioral health
By research site
VA Connecticut Healthcare System· West Haven, CT

Related Studies